Latest From Apotex Inc.
In addition to securing supply for the short term amid the coronavirus pandemic, Apotex is also “actively preparing for longer term scenarios,” as Canada’s largest pharmaceutical manufacturer and API producer.
Don't Assume Your ANDA Will Be Designated, US FDA Tells Aspiring Competitive Generic Therapy Sponsors
Final guidance clarifies that all sponsors who want CGT designation, which can bring exclusivity upon approval, should request it.
A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Apotex Inc.
- Senior Management
- Jeremy B Desai, PhD, Pres. & CEO
- Contact Info
Phone: (800) 268-4623
150 Signet Dr.
Toronto, M9L IT9
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.